by Rhoda Wilson, Expose News:
The US government funded Peter Daszak’s ECO Health Alliance to the tune of $61,491,183 to make new coronaviruses that are infectious to humans. It also directly or indirectly funds the Wuhan Institute of Virology to the tune of $7.4 million dollars to make new coronaviruses that are infectious to humans. Meanwhile, the National Institute of Allergy and Infectious Diseases funded Ralph Baric to the tune of $46,958,414 to make new coronaviruses that are infectious to humans.
This totals more than $114 million in the period from 2000 to 2020 to make new coronaviruses which are infectious to humans.
There is no question that SARS CoV 2 (causing Covid-19) is man-made. Here’s the evidence…
TRUTH LIVES on at https://sgtreport.tv/
By a concerned reader
A Brief History of man-made pathogens designed by Baric, Daszak, Zhengli and Moderna and funded by Fauci, the NIH, the NIAID and the US Government to carry out the research necessary for the creation of SARS, MERS and Covid-19 –
1984: Dr Anthony Fauci is appointed director of the NIAID (National Institute of Allergies and Infectious diseases) – There is an Orwellian Appointment for you.
1986 July1: https://grantome.com/grant/NIH/R01-AI023946-01 1986 – 1999 funding amounts not specified and then funded by $1,987,840 over 7 years from 2000 to 2007 excluding 2002.
NIAID (National Institute of Allergies and Infectious Diseases) funding Ralph Baric at University of North Carolina, Chapel Hill.
Subject: Mechanism of MHV Replication (Mouse Hepatitis Virus). This was the start of the partnership between Fauci and Baric.
1999: U.S. Dept. of Health & Human Services (HHS) funds research amplifying the infectious character of Coronaviruses.
1999: The Bill and Mellisa Gates Foundation set up GAVI (Global Alliance for Vaccines and Immunization) with a promise of $750 million in funding. So it was never going to be a bit part actor in the vaccine movie. – https://www.gavi.org/operating-model/gavis-partnership-model/bill-melinda-gates-foundation
2000: In May Ralph Baric successfully constructs a 28k base pair Coronavirus from smaller fragments by reverse transcription (making DNA from RNA) He makes an infectious TGE (Transmissible Gastroenteritis Virus – which is a type of Coronavirus) clone from isolated components of the genome. He files for US Patent 6,593,111 B2: The invention is exemplified by, although not limited to, the assembly of full-length, functional coronavirus genomes.
The present inventors have successfully assembled a full length infectious clone of transmissible gastroenteritis virus (TGE). Using a novel approach, six adjoining cDNA subclones that span the entire TGE genome were isolated. Each clone was engineered with unique flanking interconnecting junctions which dictate a precise, systematic assembly with only the correct adjacent cDNA subclones, resulting in an intact TGE cDNA construct of about approximately 28.5 Kb in length – https://patents.justia.com/patent/6593111 .
Among other advantages, full-length infectious clones of TGE permit the precise genetic modification of the coronavirus genome – https://patents.justia.com/patent/6593111
2001: April 20: NIH Grant GM63228 funds Ralph Baric et al at the University of North Carolina at Chapel Hill to do Chimera research to transform the original SARS Coronavirus which was pathogenic only to animals, existing in nature as a pathogen for dogs and rabbits, to make it pathogenic to mankind targeting lung epithelial cells. The justification for this research was that it was supposedly designed as a vector virus to distribute HIV vaccines. This resulted in US patent application US28531801P
2001 May21: Ralph Baric and Boyd Yount (Assigned to the University of North Carolina at Chapel Hill) file US Patent 6,593,111 B2 Directional Assembly of Large Viral Genomes and Chromosomes The Patent Office search report found: Lai, Michael M.C “The making of infectious viral RNA: No size limit in sight” PNAS vol 97 No 10, May 9, 2000 pp 5025-5027 And it found: Thiel et al “Infectious RNA transcribed in vitro from a cDNA copy of human coronavirus genome cloud in vaccinia virus 92: 1273-1261 (2001)
2002: April 19: The University of North Carolina files US patent 7279327 for an infectious replication defective coronavirus (to be used as a virus vector for an HIV vaccine), claiming priority from US28531801P. Inventors were: Kristopher M. Curtis, Boyd Yount, Ralph S. Baric
https://www.webmd.com/lung/news/20030411/sars-timeline-of-outbreak
2002 November 16: The first case of an atypical pneumonia is reported in the Guangdong province in southern China.
2003 February 25: First cases of unusual pneumonia reported in Hanoi, Vietnam.
2003 February 28: WHO officer Carlo Urbani, MD, examines an American businessman with an unknown form of pneumonia in a French hospital in Hanoi, Vietnam.
2003 March10: Urbani reports an unusual outbreak of the illness, which he calls sudden acute respiratory syndrome or SARS, to the main office of the WHO. He notes that the disease has infected an unusually high number of healthcare workers (22) at the hospital (in Hanoi, Vietnam).
2003 March11: A similar outbreak of a mysterious respiratory disease is reported among healthcare workers in Hong Kong.
2003 March15: WHO issues a heightened global health alert about the mysterious pneumonia with a case definition of SARS after cases in Singapore and Canada are also identified. The alert includes a rare emergency travel advisory to international travellers, healthcare professionals and health authorities.
2003 March17: An international network of 11 leading laboratories is established to determine the cause of SARS and develop potential treatments.
2003 March24: CDC officials present the first evidence that a new strain of a virus most frequently associated with upper respiratory infections and the common cold in humans called the coronavirus might be a likely cause of SARS.
2003 March29: Carlo Urbani, who identified the first cases of SARS, dies as a result of the disease. Researchers later suggest naming the agent that causes the disease after the infectious disease expert.
